Experience with immune monitoring in lung transplant recipients: Correlation of low immune function with infection

Transplantation

Volumn 87, Issue 12, 2009, Pages 1852-1857

  Husain, Shahid ^a,b   Raza, Kashif ^a   Pilewski, Joseph M ^a   Zaldonis, Diana ^a   Crespo, Maria ^a   Toyoda, Yoshi ^a   Shutt, Kathleen ^a   Spichty, Kathy ^a   Bentlejewski, Carolyn ^a   Pakstis, Diana L ^a   Carey, Mary Ellen ^a   McCurry, Kenneth R ^a   Zeevi, Adriana ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Aspergillosis; Bacterial infections; Cytomegalovirus; Immune monitoring; Lung transplantation

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; DAPSONE; METHYLPREDNISOLONE; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL PNEUMONIA; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNITY; IMMUNOASSAY; INFECTION; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; TRACHEOBRONCHITIS; VIRUS INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DAPSONE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; MYCOSES; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; VIRUS DISEASES;

EID: 67649588841     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a75ad2     Document Type: Article

References (26)

1. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77.
2. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17: 357.
3. Rubin RH, Schaffner A, Speich R. Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. Clin Infect Dis 2001; 33(suppl 1): S1.
4. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1: 21.
5. Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol 2002; 12: 125.
6. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77.
7. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130: 528.
8. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83: 1330.
9. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
10. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1.
11. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77.
12. Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14: 211.
13. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204.
14. Sampson VB, Dunn SP, Rymeski B, et al. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients. J Pediatr Surg 2008; 43: 1134.
15. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280.
16. Thai NL, Blisard D, Tom K, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation 2006; 82: 1649.
17. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005; 15: 17.
18. Gupta S, Mitchell JD, Markham DW, et al. Utility of the cylex assay in cardiac transplant recipients. J Heart Lung Transplant 2008; 27: 817.
19. Bhorade SM, Janata K, Vigneswaran WT, et al. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008; 27: 990.
20. Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7: 471.
21. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.AmJ Transplant 2008; 8: 338.
22. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
23. Singh N. Antifungal prophylaxis in solid organ transplant recipients: Considerations for clinical trial design. Clin Infect Dis 2004; 39: S200.
24. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195.
25. Husain S, Zaldonis D, Kusne S, et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006; 8: 213.
26. Pukhalsky AL, Kapranov NI, Kalashnikova EA, et al. Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection. Mediators Inflamm 1999; 8: 159.